Education

Biography

Dr. Cody P Coyne is Professor of Molecular Pharmacology and Immunology in the department of basic science at Mississippi State University College of Veterinary Medicine at Wise Center. His research interests are Pharmaceutical design, Pharmaceutical synthesis, Chemotherapy / Oncology, Immunology.

He is a veterinary doctoral graduate from the University of California. He is elected as Robert Holland Faculty Senate President at Mississippi State University. He is Faculty Organization President in the college of veterinary medicine, Mississippi State University.

Research Interest

• Pharmaceutical design
• Pharmaceutical synthesis
• Chemotherapy / Oncology
• Immunology

Scientific Activities

Membership in Professional Associations and Organizations: Past and Present

• American Veterinary Medical Association (AVMA: CSU/UCD/KSU/MSU)
• American College of Veterinary Internal Medicine (ACVIM Diplomat Status 1992)*
• American Society of Clinical Oncology (ASCO: elected member 1994)
• American Academy of Veterinary Pharmacology (AAVPT)
• American Society of Clinical Pharmacology and Therapeutics (ASCPT)
• American Association of Equine Practitioners (AAEP)
• American Association of Pharmaceutical Scientists (AAPS: pending)
• Gamma Sigma Delta
• Phi Kappa Phi Honor Society
• Phi Zeta Society
• Sigma Xi Society of Scientific Research
• California Veterinary Medical Association (CVMA: Inactive status)
• Colorado Veterinary Medical Association (CVMA: Inactive status)
• Idaho Veterinary Medical Association (IVMA: Inactive status)
• Kansas Veterinary Medical Association (KVMA: Inactive status)
• Mississippi Veterinary Medical Association (MVMA: Inactive status)
• Montana Veterinary Medical Association (MVMA: Inactive status)
• Wyoming Veterinary Medical Association (WVMA: Inactive status)

Honors and Awards

Publications

1. Pincus SH, Song K, Maresh GA, Frank A, Worthylake D, Chung HK, Polacino P, Hamer DH, Coyne CP, Rosenblum MG, Marks JW, Chen G, Weiss D, Ghetie V, Vitetta ES, Robinson JE, Hu SL. Design and In-Vivo Characterization of Immunoconjugates Targeting HIV gp160. J. Virology 2017 91(3) (20170118) NLM ID: 0113724 / DOI: 10.1128/JVI.01360-16 JVI.01360-16.
2. Coyne CP (MSU), Narayanan L. Gemcitabine-(5’-phosphoramidate)-[anti-IGF-1R]: Molecular Design, Synthetic Organic Chemistry Reactions, and Antineoplastic Cytotoxic Potency in Populations of Pulmonary Adenocarcinoma (A549). Chemical Biology and Drug Design December 20, 2016 DOI: 10.1111/cbdd.12845.
3. Coyne CP (MSU), Narayanan L. Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: Molecular Design, Synthetic Organic Chemistry Reactions and Anti-Neoplastic Cytotoxic Potency Against Pulmonary Adenocarcinoma (A549). Journal of Drug Design, Development and Therapy 2016 10 2575-2597.
4. Coyne CP (MSU), Narayanan L. Fludarabine-(C2-methylhydroxyphosphoramide)-[anti-IGF-1R]: Synthesis and selectively “targeted” anti-neoplastic cytotoxicity against pulmonary adenocarcinoma (A549). Journal of Pharmaceutics and Drug Delivery Research 2015; 4(1): 129. (NIHMS709431 / doi:10.4172/2325-9604.1000129).
5. Coyne CP (MSU), Jones T, Bear R. Simultaneous dual selective targeted delivery of two covalent gemcitabine immunochemotherapeutics and complementary anti-neoplastic potency of [Se]-methylselenocysteine. J Cancer Therapy. 2015 6, 62-89.
6. Coyne CP (MSU), Jones T, Bear R. Anti-neoplastic cytotoxicity of gemcitabine-(C4-amide)-[anti-EGFR] in dual combination with epirubicin-(C3-amide)-[anti-HER2/neu] against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) and the complementary effect of mebendazole. J Cancer Res Therapeutic Oncol. 2014 2(1), 1-23.
7. Coyne CP (MSU), Jones T, Bear R. Anti-Neoplastic cytotoxicity of gemcitabine-(C4-amide)-[anti-HER2/neu] in combination with griseofulvin against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3). Medicinal Chemistry Journal 2013 3(2):210-223.
8. Coyne CP (MSU), Jones T, Bear R. Gemcitabine-(C4-amide)-[anti-HER2/neu] anti-neoplastic cytotoxicity in dual combination with mebendazole against chemotherapeutic-resistant mammary adenocarcinoma. J Clinical Experimental Oncology (Special Issue: Cancer Prevention and Therapy) 2013: 2.2:1-13.
9. Coyne CP (MSU), Jones T, Bear R. Synthesis of gemcitabine-(C4-amide)-[anti-HER2/neu] utilizing a UV-photoactivated gemcitabine intermediate: cytotoxic anti-neoplastic activity against chemotherapeutic-resistant mammary adenocarcinoma SKBr-3. J Cancer Therapy: Breast Cancer Special Issue 2012; 3: 689-711.
10. Coyne CP (MSU), Jones T, Bear R. Influence of alternative tubulin inhibitors on the potency of epirubicin-immunochemotherapeutic synthesized with an ultra violet light-activated intermediate.
11. Cancer and Clinical Oncology, 2012: 1(2) 49-80.
12. Coyne CP (MSU), Jones T, Bear R. Synthesis of a covalent epirubicin-(C3-amide)-[anti-HER2/neu] immunochemotherapeutic utilizing a UV-photoactivated anthracycline intermediate.
13. Cancer Biotherapy and Radiopharmaceuticals, 2012:27(1) 41-55.
14. Coyne CP (MSU), Jones T, Sygula A, Bailey J, Pinchuk L. Epirubicin-[anti-HER2/neu] synthesized with an epirubicin-(C13-keto) EMCS intermediate: anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary adenocarcinoma in combination with organic selenium. Journal of Cancer Therapy. 2011;2(1):22-39.
15. Coyne CP (MSU), Jones T, Pharr T. Synthesis of a covalent gemcitabine-(carbamate)-[anti-HER2/neu] immunochemotherapeutic and cytotoxic anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary adenocarcinoma. Bioorganic and Medicinal Chemistry 2011;19:67-76.
16. Coyne CP (MSU), Ross MK, Bailey JG. Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary adenocarcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition. Journal of Drug Targeting 2009;17(6):474-489.
17. Coyne CP (MSU), Rashmir-Raven A, Jones T, Mochal C, Linford RL, Brashier M, Eddy A. Delineation of pulmonary airway fluid protein fractions with HRPO binding-avidity by far-Western ligand blot and mass spectrometry analyses: A model methodology for detecting mannose-binding protein expression profiles. ACTA BioMedica 2009;80:243-261.
18. Coyne CP (MSU), Cadillac JM. SPECIAL REPORT Factors Associated with Amounts of Research Funding Obtained from the National Institutes of Health by Colleges and Schools of Veterinary Medicine. Am J Vet Res 2008; 69(12):1676-1685 (Reviewed: AVMA Research Board and CVM Deans, AJVR Editorial Board).
19. Coyne CP (MSU), Howell T, Baravik J, Baravik E, Fenwick BW, Willetto C. Biochemical mechanisms influencing the expression of membrane-associated TNF RII (75-kDa) and IL-1 RI (80 kDa) receptor complexes in adherent populations of vascular endothelium. Pathophys 2003;9:115-125.
20. Coyne CP (MSU), Howell T, Smodlaka H, Willetto C, Fenwick BW, Chenney E. Alterations in membrane-associated CD14 expression and the simultaneous liberation of soluble CD14 fragment in adherent macrophages mediated by a leukocyte carboxyl/aspartate protease.. Journal of Endotoxin Res 2002;8:273-283.
21. Coyne CP (MSU), Baravik J, Baravik E, Howell T, Fenwick BW, Willetto C. Biochemical alteration of membrane-associated IL-6 RI (80-kDa) shedding in populations of adherent macrophages and vascular endothelium. Molecular Immunology 2001;38:347-357.
22. Coyne CP (MSU), Baravik J, Howell T, Baravik E, Fenwick BW, Willetto C. Biochemical mechanisms that interact with membrane-associated IL-1 RII (60-kDa decoy) receptors in populations of adherent macrophages and vascular endothelium. Cellular Signaling 2001;12;765-776.
23. Coyne CP (MSU), Brake D. Characterization of Haemonchus contortus-derived cell populations propagated in-vitro in a tissue culture environment and their potential to induce protective immunity in sheep. International Journal of Parasitology 2001;31:359-376.
24. Coyne CP (MSU), Willetto C, Fenwick BW. A mechanism of TNFR Type II (75-kDa) “shedding” in macrophages. Shock 1999;1:19-30. (major professor for Masters graduate student).
25. Pond AL, Chambers HW, Coyne CP (MSU), Chambers JE. Purification of two rat hepatic proteins with A-esterase activity. J Pharm Exp Therapy 1998;286:1404-1411.
26. Wilson JM, Coyne C (MSU), Glen DM. Low Temperatures Suppress Growth of the Ciliate Parasite, Tetrahymena rostrata , and Pathogenicity to Field Slugs, Deroceras reticulatum. Biocontrol Sciences and Technology 1998 8(1) 181-184.
27. Coyne CP (MSU), Fenwick BW, Ainsworth J. Anti-neoplastic activity of chemotherapeutic "loaded" neutrophils against human mammary adenocarcinoma. Biotherapy 1997;10:145-159.
28. Pond AL, Coyne CP (MSU), Chamber HW, Chambers JE. Identification and isolation of two rat serum proteins with A-esterase activity towards paraoxon and chlorpyrifos-oxon. Biochem Pharm 1996;52:363-369.
29. Coyne CP (MSU), Moritz JT, Fenwick BW. Inhibition of lipopolysaccharide-induced TNF-alpha production by semisynthetic polymyxin-B conjugated dextran. Biotechnology Therapeutics 1995, 5(3-4) 137-162. (MSU: Application Submitted to United States Patent Office).
30. Coyne CP (MSU), Moritz J. Semi-synthesis of polymyxin-B conjugated ovalbumin: evaluation of lipopolysaccharide binding-avidity and neutralization of induced TNF- synthesis. Biotherapy 1995;8:69-83 (MSU: Application Submitted to United States Patent Office).
31. Coyne CP (MSU), Moritz J. Design of a semi-synthetic (polymyxin-B•biotin)4|avidin tetramer and evaluation of it's ability to inhibit lipopolysaccharide induced TNF- synthesis. J Endotox Res 1994;1(4) 207-215. (MSU: Application Submitted to United States Patent Office).
32. Coyne CP (KSU), Fenwick BW, Iandola J, Griffith G, Williams D. Isolation of an inhibitor of tumor necrosis factor-alpha-mediated cytotoxicity liberated from chemotaxin-stimulated equine white blood cell populations. Am J Vet Res 1993;54:845-855.
33. Coyne CP (KSU), Fenwick BW. Inhibition of lipopolysaccharide-induced macrophage TNF- synthesis by polymyxin-B. Am J Vet Res 1993;54:305-314.
34. Erickson HH, Olsen S, Pelletier N, Lowe B, Coyne CP (KSU). Exercise induced pulmonary hemorrhage in equine athletes. Eq Nutr Physiol Proc 1993;13:132-133. (co-major professor for PhD graduate students).
35. Erickson HH, Olsen S, Pelletier N, Lowe B, Coyne CP (KSU). Reversal of furosemide induced hemodynamic alteration by NSAIDS. Am Assoc Eq Pract. 1993;735-738. (co-major professor for PhD graduate students).
36. Coyne CP (KSU), Smith JE, Keeton K. Additive and synergistic pharmacological inhibition of factor XIIIa*-like biochemical activity. Am J Vet Res 1992;53:2058-2066.
37. Coyne CP (KSU), Smith JE, DeBowes RM. Pharmacologic evaluation of factor XIIIa*-like enzyme activity in equine plasma as a potential therapeutic avenue for the inhibition of fibrinous tissue. Am J Vet Res 1992;53:695-705.
38. Rashmir A, Coyne CP (KSU), Fenwick B, DeBowes R. Inhibition of equine complement by therapeutic polysulfated glycosaminoglycans (Adequan). Am J Vet Res 1992;53:87-90.
39. Olsen SC, Coyne CP (KSU), Lowe BS,* Pelletier N,* Raub EM, Erickson HH. Influence of cyclooxygenase inhibitors on furosemide-induced hemodynamic effects during exercise in horses. Am J Vet Res 1992;53:1562-1567. (co-major professor for PhD graduate students).
40. Coyne CP (UC-Davis), Carlson GP, Spensley M, Case J. Preliminary investigation of alterations in blood viscosity, cellular composition, and electrophoresis plasma protein faction profile after competitive racing activity in Thoroughbred horses. Am J Vet Res 1990;51:1956-1963.
41. Coyne CP (UC-Davis), Kelly AB, Hornof WJ, O'Brien TR, Phelps MS, Lamb JF. Radiolabeling of equine platelets in plasma with [111In]-2‑mercaptopyridine‑N‑oxide and their in-vivo survival in the horse. Am J Vet Res 1987;48:385-391.
42. Coyne CP (UC-Davis), Hornof WJ, Kelly AB, O'Brien TR, DeNardo SJ. Extraction, radio­iodination, and in-vivo catabolism of equine fibrinogen. Am J Vet Res 1985;46:2572‑2577.
43. Coyne CP (UC-Davis), Hornof WJ, Kelly AB, O'Brien TR, DeNardo SJ. Rapid extraction, radioiodination, and in-vivo catabolism of [125I]‑labeled fibrinogen in the horse. Am J Vet Res 1985:46:2578‑2581.